Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma

BACKGROUND: Multiple myeloma (MM) remains an incurable malignancy, despite the advent of therapies such as proteosome inhibitors (PIs) that disrupt protein homeostasis and induce ER stress. We have pursued inhibition of geranylgeranyl diphosphate synthase (GGDPS) as a novel mechanism by which to tar...

Descripción completa

Detalles Bibliográficos
Autores principales: Haney, Staci L., Varney, Michelle L., Williams, Jacob T., Smith, Lynette M., Talmon, Geoffrey, Holstein, Sarah A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827146/
https://www.ncbi.nlm.nih.gov/pubmed/35139925
http://dx.doi.org/10.1186/s40164-022-00261-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827146/
https://www.ncbi.nlm.nih.gov/pubmed/35139925
http://dx.doi.org/10.1186/s40164-022-00261-6

Ejemplares similares